175 related articles for article (PubMed ID: 33290351)
1. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol; 2021 Jan; 40(1):17-23. PubMed ID: 33290351
[TBL] [Abstract][Full Text] [Related]
2. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
Buza N
Arch Pathol Lab Med; 2021 Jun; 145(6):687-691. PubMed ID: 32649220
[TBL] [Abstract][Full Text] [Related]
3. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
Buza N; English DP; Santin AD; Hui P
Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N; Hui P
Arch Pathol Lab Med; 2022 Jun; 146(5):0. PubMed ID: 35687792
[TBL] [Abstract][Full Text] [Related]
5. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
Buza N; Euscher ED; Matias-Guiu X; McHenry A; Oliva E; Ordulu Z; Parra-Herran C; Rottmann D; Turner BM; Wong S; Hui P
Mod Pathol; 2021 Jun; 34(6):1194-1202. PubMed ID: 33536574
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
Buza N; Roque DM; Santin AD
Arch Pathol Lab Med; 2014 Mar; 138(3):343-50. PubMed ID: 24576030
[TBL] [Abstract][Full Text] [Related]
8. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
[TBL] [Abstract][Full Text] [Related]
9. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Hagemann IS; Bridge JA; Tafe LJ; Hameed MR; Moncur JT; Bellizzi AM; Dolan M; Vasalos P; Kane ME; Souers RJ; Yemelyanova A
Arch Pathol Lab Med; 2023 Oct; 147(10):1148-1157. PubMed ID: 36538387
[TBL] [Abstract][Full Text] [Related]
10. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
[TBL] [Abstract][Full Text] [Related]
11. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
12. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma.
Talia KL; Banet N; Buza N
Pathology; 2023 Feb; 55(1):8-18. PubMed ID: 36503635
[TBL] [Abstract][Full Text] [Related]
13. Expression of HER2 and EGFR Proteins in Advanced Stage High-grade Serous Ovarian Tumors Show Mutual Exclusivity.
Crasta J; Ravikumar G; Rajarajan S; Gali S; Kulkarni KA; Vallikad E; Prabhu J
Int J Gynecol Pathol; 2021 Jan; 40(1):49-55. PubMed ID: 32287114
[TBL] [Abstract][Full Text] [Related]
14. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas.
Ersoy E; Cao QJ; Otis CN
Int J Gynecol Pathol; 2022 Jul; 41(4):313-319. PubMed ID: 34320531
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Sill MW; Darcy KM; McMeekin DS; Thigpen JT; Adler LM; Berek JS; Chapman JA; DiSilvestro PA; Horowitz IR; Fiorica JV
Gynecol Oncol; 2010 Jan; 116(1):15-20. PubMed ID: 19840887
[TBL] [Abstract][Full Text] [Related]
17. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
19. Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.
Chui MH; Brown DN; Da Cruz Paula A; da Silva EM; Momeni-Boroujeni A; Reis-Filho JS; Zhang Y; Makker V; Ellenson LH; Weigelt B
J Pathol; 2024 Feb; 262(2):129-136. PubMed ID: 38013631
[TBL] [Abstract][Full Text] [Related]
20. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
